Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apremilast in pediatric moderate to severe plaque psoriasis
NL-OMON55888Phase 3Completed
- Sponsor
- Amgen
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in plaque psoriasis comparing Apremilast with Placebo then apremilast (2 arms). Primary endpoint: sPGA response at Week 16. Started Feb 2020; status: completed.
02
Drugs
apremilast
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NL-OMON55888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55888.